In the Boardroom
Refine Search
Biotechnology
US rare disease company aTyr Pharma has named John McKew as vice president of research. 22 October 2014
article
UK-based inflammatory disease and cancer specialist Karus Therapeutics has appointed Simon Roitt as head of clinical development and Peter Finan as head of biology. 21 October 2014
article
Therapeutic antibody specialist AnaptysBio has appointed Marco Londei as chief development officer, leading the preclinical and clinical development of AnaptysBio’s proprietary antibody pipeline. 20 October 2014
Pharmaceutical
German pharma company Grünenthal Group has appointed Sascha Becker as group chief financial officer, commencing in the first quarter of 2015. 20 October 2014
Pharmaceutical
James Bowling, interim chief financial officer of Ireland-headquartered drugmaker Shire, has stepped down from the position. 20 October 2014
Pharmaceutical
Swedish drug developer Karolinska Development has named Bruno Lucidi as permanent chief executive. 15 October 2014
Pharmaceutical
Although life science company boards are recruiting more women, a lack of managing their talent during their career is slowing the progress towards greater diversity, according to life sciences human resources specialist RSA’s biannual survey of non-executive directors. 14 October 2014
Pharmaceutical
Swedish orphan and niche product specialist Pharmalink has appointed Bengt Julander as chairman of the board of directors, replacing Anders Wiklund. 14 October 2014
Pharmaceutical
Swiss drug major Novartis has announced that three members of its executive committee will leave the company. 9 October 2014
Pharmaceutical
European specialty pharmaceutical company Norgine has appointed Christopher Bath as vice president of global finance. 8 October 2014
Pharmaceutical
Japan’s largest drugmaker Takeda Pharmaceutical has appointed John Boslego as senior vice president and head of development for the company’s global vaccine business unit. 8 October 2014
Pharmaceutical
Canadian biopharmaceutical company Aeterna Zentaris has named Philip Theodore as senior vice president, chief administrative officer, general counsel and corporate secretary. 7 October 2014
Biotechnology
PDL BioPharma has appointed Danny Hart as vice president of business development. 6 October 2014
Pharmaceutical
Satish Jindal has been appointed to lead the discovery of drug candidates from leading academic institutions at Allied-Bristol Life Sciences, a jointly-owned enterprise between Allied Minds and US drug major Bristol-Myers Squibb. 6 October 2014
Pharmaceutical
US-based clinical biopharmaceutical company Mast Therapeutics has named Edwin Parsley, has joined the company as its chief medical officer and senior vice president. 2 October 2014
Pharmaceutical
US pain therapeutic specialists Relmada Therapeutics has appointed Julie Chen as its Director of Finance and Operations. 2 October 2014
Pharmaceutical
USA-based specialty pharmaceutical company Zynerba Pharmaceuticals, focused on innovative transdermal cannabinoid treatments, has named two leading industry veterans to lead the company. 2 October 2014
Pharmaceutical
Privately-held gastrointestinal company Ritter Pharmaceuticals has appointed Michael Step as chief executive. 1 October 2014
Biotechnology
Cancer-focused genetic testing service provider NeoGenomics has appointed Robert Shovlin as chief operating officer. 30 September 2014
Biotechnology
Swedish drug developer Karolinska Development has appointed current board member Klaus Wilgenbus as chief executive on an interim basis, following the departure of Torbjörn Bjerke from the position. 30 September 2014
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
Anthony Harnden has been appointed as the new chair of the UK’s Medicine and Healthcare products Regulatory Agency (MHRA). 20 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Pharmaceutical
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze